Ebola

Sharon Carrasco DNP, APRN, ACNS-BC, ANP-C, CEN, FAEN, FAAN, FNAP, talks about safely responding to deadly pathogens such as Ebola and Lassa fever, and where the US is in terms of thinking about preparedness on a national level.

Gavin Harris, MD, discusses his experience working in outbreak environments where there is high-consequence infectious disease (HCID) and how it is important to establish buy-in from the local populations and some of the important elements of what you need to leave behind when an outbreak is declared over.

Democratic Republic of the Congo reports 28 suspected cases and 15 deaths, as Africa CDC and WHO mobilize vaccines, surveillance, and rapid response teams to contain the 16th Ebola outbreak since 1976.

In the second interview segment with leaders from UNC's Special Pathogen Center, they discuss what it is like to be in the field during an outbreak caring for patients with high-consequence infectious diseases, and offer insights on how well prepared the US is for these situations.

During the 2014-2016 African epidemic, investigational Ebola vaccines demonstrated safety and immunogenicity.

This first-in-human, phase 1 vaccine trial produced a lasting immune response against Marburg virus.

After their first Sudan ebolavirus outbreak in 10 years, resulting in 164 cases, Uganda today announced the Ebola outbreak is over.

That country is trying to contain the virus to prevent further cases, as well as other African countries met to try to prevent an outbreak inside their own borders.

Uganda’s first Ebola outbreak in a decade raises concern due to its vaccine resistance.

2 patients died of Marburg virus in the southern Ashanti region of Ghana. Nearly 100 close contacts are now under observation for the infectious disease, which is a cousin of the Ebola virus.

The CDC’s Advisory Committee on Immunization Practices voted to recommend hepatitis B, orthopoxviruses, and Ebola vaccines to certain populations, as well as approving 2022 immunization schedules for children, adolescents, and adults.

Johnson & Johnson’s vaccine regimen induced neutralizing antibody responses in 98% of participants 21 days after the second dose.

The first case reported in Guinea has resulted in a patient's death, while health authorities work to reduce outbreak risks.

EVD outbreaks this year serve as a reminder of the virus’ severity and the importance of having a containment strategy in place.

The recombinant human IgG1κ monoclonal antibody binds and neutralizes the virus.

The Democratic Republic of the Congo (DRC) reached 42 days without a new case. Guinea, however, has not officially declared its outbreak over yet.

Infectious diseases are emerging at an alarmingly rapid pace, faster than any other time in human history.

An outbreak which began at an infected healthcare worker's funeral has resulted in nearly 100 contact follow-ups.

Beginning this week, the agency is funneling air travelers from 2 African countries to a limited amount of US airports.

Just months removed after its last outbreak, the country is seeing the emergence of another outbreak.

The Ebola vaccine is not commercially available, but can be distributed upon request to the CDC and administered under the supervision of a physician.

An Orphan Drug Designation was granted to Ridgeback Biotherapeutics, LP, creator the therapy.

Here is a look at the patterns within the variety of symptoms and presentations during physician exams.

John Johnson, lead for Ebola vaccination with MSF France, describes the "ring strategy" used in controlling several infectious disease threats.